+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06760819

Evaluating Oral BAY2927088 Sevabertinib in Adults With Metastatic or Unresectable Solid Tumors Having HER2-Activating Mutations

Led by Bayer · Updated on 2026-11-04

111

Participants Needed

54

Research Sites

38 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well BAY2927088 sevabertinib works and how safe it is for adults with solid tumors that have HER2-activating mutations. The study focuses on tumors in the colon, rectum, uterus, cervix, breast, bladder, biliary tract, and other solid tumors, excluding advanced non-small cell lung cancer NSCLC. The abnormal HER2 protein in cancer cells may cause increased growth, and this treatment aims to block that protein. Participants will take 20 mg of BAY2927088 tablets by mouth twice daily in 3-week cycles. They will continue treatment until their cancer worsens, they face medical issues, or choose to leave the study. This is a single-group, open-label Phase 2 study involving about 111 adult participants with metastatic or unresectable tumors. During the trial, doctors will monitor participants using imaging scans to track cancer spread and heart health assessments including echocardiograms, cardiac MRI, and electrocardiograms. Blood and urine samples, physical exams, and questionnaires about health and symptoms will also be collected. The main outcome measured is the objective response rate according to RECIST 1.1 criteria, with follow-up up to about 3 years.

CONDITIONS

Brief Title

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Research Team

B

Bayer Clinical Trials Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here